Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
morfiacidine
- Development stage
- Phase 1
- Lead developer
- Sunshine Lake Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Morfiacidine is a small molecule hepatitis B virus (HBV) capsid assembly modulator (CpAM) developed by HEC Pharm (Dongguan Chang'an Dongyangguang New Drug Research and Development). It belongs to the heteroaryldihydropyrimidine (HAP) class of inhibitors. The drug targets the HBV core protein (HBcAg), interfering with the assembly of the viral capsid. By inducing the formation of empty or defective capsids, it prevents the packaging of pre-genomic RNA and the subsequent replication of the viral genome. Morfiacidine has been evaluated in Phase 1 clinical trials for the treatment of chronic hepatitis B to determine its safety, tolerability, and pharmacokinetic profile.
- Other names
- morfiacidine mesylate莫非西定
02
Targets
HBc (Hepatitis B virus core protein)
Beyond the preview
Go deeper on morfiacidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on morfiacidine.